NCT06074029 2024-02-08
Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy
Peking Union Medical College Hospital
Phase 1/2 Unknown
Clinical Trials
53 trialsNCT06202781 2024-01-12
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
Chinese PLA General Hospital
Unknown
NCT05248022 2024-01-09
Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT05588219 2023-11-24
Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
First Affiliated Hospital of Guangxi Medical University
Phase 2 Unknown
NCT06047860 2023-09-21
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05994456 2023-08-16
Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05871684 2023-08-01
A Combination Study of CAR-T Therapy in r/r B-NHL
Ruijin Hospital
Phase 2 Unknown
NCT05913583 2023-06-22
Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT05913661 2023-06-22
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05845268 2023-05-06
Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer
Beijing Friendship Hospital
Phase 2 Unknown
NCT05790447 2023-03-30
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05218629 2023-03-29
Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer
Qingdao Central Hospital
Phase 2 Unknown
NCT05775874 2023-03-20
A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
Abbisko Therapeutics Co, Ltd
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05163483 2023-03-06
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05609695 2023-01-31
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma
Sun Yat-sen University
Unknown
NCT04459078 2022-12-02
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
Hunan Cancer Hospital
Phase 2 Unknown
NCT05605613 2022-11-09
PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial
The First Affiliated Hospital of Zhengzhou University
Phase 2/3 Unknown
NCT05603013 2022-11-02
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05509478 2022-09-10
LEADER-001
The First Hospital of Jilin University
Phase 2 Unknown
NCT05520853 2022-08-30
SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT04892498 2022-08-09
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05374252 2022-05-16
Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Unknown
NCT05371197 2022-05-12
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Unknown
NCT05325684 2022-04-13
PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer
The Affiliated Hospital of Qingdao University
Phase 1/2 Unknown
NCT05322187 2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3 Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT05007145 2021-12-21
REVO
Fujian Cancer Hospital
Phase 2 Unknown
NCT05137886 2021-12-17
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04814043 2021-09-22
PLATIC
Sun Yat-sen University
Phase 2 Unknown
NCT05035381 2021-09-05
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03943472 2021-08-31
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04539444 2021-08-02
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04922450 2021-06-10
Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
Hunan Cancer Hospital
Phase 2 Unknown
NCT04922541 2021-06-10
Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
Second Affiliated Hospital, School of Medicine, Zhejiang University
Unknown
NCT04913896 2021-06-04
CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy
The First Hospital of Jilin University
Unknown
NCT04864379 2021-04-28
Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors
Sir Run Run Shaw Hospital
Phase 1 Unknown
NCT04814030 2021-04-23
AIPD-1
Sun Yat-sen University
Phase 2 Unknown
NCT04769076 2021-02-25
The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT04137588 2021-02-24
Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Unknown
NCT04229355 2021-02-09
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Phase 3 Unknown
NCT03989310 2020-12-23
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT04613804 2020-11-03
Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy
Fujian Cancer Hospital
Phase 2 Unknown
NCT04419441 2020-09-16
ICI-RT-1
Ospedale Maggiore Di Trieste
Unknown
NCT03987698 2020-07-07
Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03987867 2020-07-07
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Unknown
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown
NCT04355806 2020-04-21
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
Shanghai Pulmonary Hospital, Shanghai, China
Unknown
NCT04353479 2020-04-20
Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT04294511 2020-03-04
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma
Sun Yat-sen University
Phase 2 Unknown